Theratechnologies Inc. (THTX)

Market Cap	79.39M
Revenue (ttm)	60.19M
Net Income (ttm)	-35.52M
Shares Out	96.81M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	55.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,043
Open	0.890
Previous Close	0.820
Day's Range	0.772 - 0.890
52-Week Range	0.700 - 2.770
Beta	1.58
Analysts	Buy
Price Target	3.71 (+352.38%)
Earnings Date	Apr 12, 2023

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 87
• Stock Exchange: NASDAQ
• Ticker Symbol: THTX

Financial Performance

In 2022, THTX's revenue was 80.06 million, an increase of 14.66% compared to the previous year's 69.82 million. Losses were -47.24 million, 48.9% more than in 2021.

Financial numbers in CAD

Analyst Forecast

According to 13 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is $3.71, which is an increase of 352.38% from the latest price.

Price Target

$3.71

(352.38% upside)

Analyst Consensus: Buy